Show simple item record

dc.contributor.authorFriedlander, M
dc.contributor.authorGebski, V
dc.contributor.authorGibbs, E
dc.contributor.authorDavies, L
dc.contributor.authorBloomfield, R
dc.contributor.authorHilpert, F
dc.contributor.authorWenzel, L
dc.contributor.authorEek, D
dc.contributor.authorRodrigues, M
dc.contributor.authorClamp, Andrew R
dc.contributor.authorPenson, R
dc.contributor.authorProvencher, D
dc.contributor.authorKorach, J
dc.contributor.authorHuzarski, T
dc.contributor.authorVidal, L
dc.contributor.authorSalutari, V
dc.contributor.authorScott, C
dc.contributor.authorNicoletto, M
dc.contributor.authorTamura, K
dc.contributor.authorEspinoza, D
dc.contributor.authorJoly, F
dc.contributor.authorPujade-Lauraine, E
dc.date.accessioned2018-09-15T19:14:23Z
dc.date.available2018-09-15T19:14:23Z
dc.date.issued2018-08
dc.identifier.citationHealth-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. 2018, 19(8): 1126-1134 Lancet Oncolen
dc.identifier.issn1474-5488
dc.identifier.pmid30026002
dc.identifier.doi10.1016/S1470-2045(18)30343-7
dc.identifier.urihttp://hdl.handle.net/10541/621234
dc.description.abstractIn the phase 3 SOLO2 trial (ENGOT Ov-21), maintenance therapy with olaparib tablets significantly prolonged progression-free survival (primary endpoint) compared with placebo in patients with a germline BRCA1 or BRCA2 (BRCA1/2) mutation and platinum-sensitive, relapsed ovarian cancer who had received two or more lines of previous chemotherapy. The most common subjective adverse effects included fatigue, nausea, and vomiting, which were typically low grade and self-limiting. Our a-priori hypothesis was that maintenance olaparib would not negatively affect health-related quality of life (HRQOL) and additionally that the prolongation of progression-free survival with olaparib would be underpinned by additional patient-centred benefits.
dc.language.isoenen
dc.rightsArchived with thanks to The Lancet. Oncologyen
dc.titleHealth-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.en
dc.typeArticleen
dc.contributor.departmentUniversity of New South Wales Clinical School, Prince of Wales Hospital, Randwick, NSW, Australiaen
dc.identifier.journalThe Lancet Oncologyen
html.description.abstractIn the phase 3 SOLO2 trial (ENGOT Ov-21), maintenance therapy with olaparib tablets significantly prolonged progression-free survival (primary endpoint) compared with placebo in patients with a germline BRCA1 or BRCA2 (BRCA1/2) mutation and platinum-sensitive, relapsed ovarian cancer who had received two or more lines of previous chemotherapy. The most common subjective adverse effects included fatigue, nausea, and vomiting, which were typically low grade and self-limiting. Our a-priori hypothesis was that maintenance olaparib would not negatively affect health-related quality of life (HRQOL) and additionally that the prolongation of progression-free survival with olaparib would be underpinned by additional patient-centred benefits.


Files in this item

This item appears in the following Collection(s)

Show simple item record